By Chris WackNRx Pharmaceuticals has received qualified infectious disease product and fast-track designation from the U.S. Food and Drug Administration for NRX-101 in the treatment of complicated urinary tract infections and pyelonephritis. Receipt of QIDP designation confers priority review, and five additional years of data-exclusivity to NRX-101's intellectual property position.

Source: Wall Street Journal January 16, 2024 23:58 UTC